Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community 2-Deoxy-D-Ribose official Product

      in Research/Science  6 upvotes 1 year ago
      2-Deoxy-D-Ribose is discussed as a potential hair loss treatment, but skepticism exists due to lack of human testing. The original poster uses a combination of topical Minoxidil, oral Finasteride, topical RU58841, and other treatments, reporting some hair regrowth but not significant results.

      community HMI-115 question about potential earliest access

      in Research/Science  10 upvotes 3 years ago
      Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

      community M29 - 4 YEARS on Dutasteride - almost no progress

      in Chat  6 upvotes 4 months ago
      The user has been on a comprehensive hair loss treatment regimen for four years, including Dutasteride, topical and oral Minoxidil, and various other treatments, but has seen little progress and is considering a hair transplant. Despite trying multiple therapies, including PRP and exosome injections, the user is still experiencing hair thinning and is hesitant about trying peptides due to potential cancer risks.

      community Has anyone gotten pp405 on the grey market yet?

      in Research/Science  10 upvotes 2 months ago
      People are discussing the use of an untested hair loss treatment called PP405, which is not available on the grey market. Some users are trying a mimic formulation called HP3, reporting thicker hair but no new growth yet.

      community Pyrilutamide Trial Phase 3 Results?

      in Research/Science  10 upvotes 2 years ago
      The conversation is about the release of Phase 3 trial results for pyrilutamide in China for treating hair loss. The user is inquiring if the actual results have been posted, noting that a recent release did not contain them.